| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
|
Lee C.K;Brown C;Gralla R.J;Hirsh V;Thongprasert S;Tsai C.-M;Tan E.H;Ho J.C.-M;Chu D.T;Zaatar A;Osorio Sanchez J.A;Vu V.V;Au J.S.K;Inoue A;Lee S.M;Gebski V;Chih-Hsin Yang; Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:53Z |
Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis
|
Chih-Hsin Yang;Gralla R.J;Gebski V;Links M;Pavlakis N;Rosell R;Mitsudomi T;Zhou C;Inoue A;Lord S.J;Ding P.N;Wu Y.-L;Lee C.K; Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non?�Small Cell Lung Cancer
|
Lee C.K.; CHIH-HSIN YANG; Gralla R.J; Bray V; Links M; Gebski V; Lord S.J; Lee C.K.;Chih-Hsin Yang;Gralla R.J;Bray V;Links M;Gebski V;Lord S.J;Ding P.N; Ding P.N |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis
|
Chih-Hsin Yang;Mok T;Gralla R.J;Herbst R.S;Gebski V;Links M;Cooper W;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst R.S; Gralla R.J; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
|
Woodford R;Loh Y;Lee J;Cooper W;Marschner I;Lewis C.R;Millward M;Lord S;Gralla R.J;Chih-Hsin Yang;Mok T;Lee C.K.; Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG; Mok T; Lee C.K. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
